NCT05523427

Probiotics as Adjuvant Therapy in the Management of Irritable Bowel Syndrome

Two Lactobacilli Strains as Adjuvant Therapy in the Management of Irritable Bowel Syndrome: A Randomized Clinical Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: University of Mosul · Academic / Other
• Sex: All
• Age: 16 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

Studying the effects of adding probiotics to the drug regimen of patients with diarrhea predominant IBS

Detailed description

Irritable bowel syndrome (IBS) is a common highly prevalent functional gastrointestinal (GI) disorder that places an enormous burden on resource-challenged healthcare systems. Although many drugs have been advocated in the treatment of IBS, including psychotropic agents, antispasmodics, bulking agents, and 5-HT receptor antagonists. However, in the vast majority of instances, these medications have failed to provide adequate symptom alleviation, presumably due to the disease's diverse pathophysiology. Probiotics are "live bacteria that confer a health benefit on the host when administered in suitable doses". In IBS, a decrease in Bifidobacterium and Lactobacillus species, as well as an increase in Gamma-proteobacteria species (a family of pathogens), has been described in IBS studies. Therefore, the ability of probiotics to repair dysbiosis (qualitative and quantitative changes in the microbiota) or stabilize the host microbiota is the reason for their use in the treatment of IBS.

Conditions

• Irritable Bowel Syndrome
• Irritable Bowel Syndrome With Diarrhea

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Two probiotic strains (L. plantarum and L. acidophilus)	A capsule containing the L. plantarum and L. acidophilus strains is to be administered twice daily for three months in addition to the standard treatment of IBS.

Timeline

• Start date: 2022-07-19
• Primary completion: 2022-12-21
• Completion: 2023-01-06
• First posted: 2022-08-31
• Last updated: 2023-01-18

Locations

1 site across 1 country: Iraq